Taiwan Liposome Company Completes US IPO

San Diego – January 3, 2019 – Cooley advised Taiwan Liposome Company on its $22.7 million initial public offering of 3,915,550 American Depository Shares – each representing two common shares. Partners Charlie Kim, Robert Phillips, James Lu and David Peinsipp led the Cooley team advising Taiwan Liposome Company.

Cantor acted as book-running manager for the offering. CLSA, HC Wainwright & Co., Janney Montgomery Scott and Laidlaw & Company UK Ltd. acted as book-runners.

Taiwan Liposome Company, whose securities now trade on the Nasdaq Global Market under the symbol “TLC,” is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology. 

Cooley has now represented the only two Taipei Exchange-listed companies to go public in the US to date – TLC and ASLAN Pharmaceuticals in June 2018

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,000+ lawyers across 13 offices in the United States, China and Europe.

 
Related Contacts
Charlie Kim  Partner San Diego, Los Angeles
James Lu  Partner Shanghai, San Diego
David Peinsipp  Partner San Francisco, Palo Alto
Kristin VanderPas  Partner San Francisco
Sara Semnani  Partner Los Angeles
Chen Chen  Associate Palo Alto
Natasha Leskovsek  Of Counsel Washington, DC
Phil Mitchell  Partner New York
Susan Cooper Philpot  Retired Partner San Francisco
Mark Windfeld-Hansen  Senior Counsel Palo Alto
Barbara Mirza  Partner Los Angeles, Palo Alto
Courtney Thorne  Partner Boston
Francis Wheeler  Partner Colorado
Daniel I. Goldberg  Partner New York
Josh Kaufman  Partner New York
Monica Xu  Counsel Shanghai
Pan Chen  Senior Legal Consultant Shanghai
Alexander Davis  Associate San Diego